Kaoru Nakanishi

Suggest Changes
Learn More
BACKGROUND Patients with epidermal growth factor receptor (EGFR) activation mutation-positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), but(More)
  • 1